These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34200459)

  • 1. Circulating Levels of the Interferon-γ-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy.
    Esteban E; Exposito F; Crespo G; Lambea J; Pinto A; Puente J; Arranz JA; Redrado M; Rodriguez-Antona C; de Andrea C; Lopez-Brea M; Redin E; Rodriguez A; Serrano D; Garcia J; Grande E; Castellano D; Calvo A
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34200459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
    Polimeno M; Napolitano M; Costantini S; Portella L; Esposito A; Capone F; Guerriero E; Trotta A; Zanotta S; Pucci L; Longo N; Perdonà S; Pignata S; Castello G; Scala S
    BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of CXCL9, CXCL10 and CXCL11 levels during primary HIV infection predicts HIV disease progression.
    Yin X; Wang Z; Wu T; Ma M; Zhang Z; Chu Z; Hu Q; Ding H; Han X; Xu J; Shang H; Jiang Y
    J Transl Med; 2019 Dec; 17(1):417. PubMed ID: 31836011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
    Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
    Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis.
    Rousseau B; Kempf E; Desamericq G; Boissier E; Chaubet-Houdu M; Joly C; Saldana C; Boussion H; Neuzillet C; Macquin-Mavier I; Oudard S; Salomon L; de la Taille A; Tournigand C
    Crit Rev Oncol Hematol; 2016 Nov; 107():44-53. PubMed ID: 27823651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
    de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
    Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.
    Mauge L; Mejean A; Fournier L; Pereira H; Etienne-Grimaldi MC; Levionnois E; Caty A; Abadie-Lacourtoisie S; Culine S; Le Moulec S; Linassier C; Théodore C; Ravaud A; Albiges L; Grine A; Tartour E; Milano G; Gille AS; Verkarre V; Helley D; Oudard S;
    Clin Cancer Res; 2018 Nov; 24(22):5534-5542. PubMed ID: 30061359
    [No Abstract]   [Full Text] [Related]  

  • 9. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes.
    Kanda N; Shimizu T; Tada Y; Watanabe S
    Eur J Immunol; 2007 Feb; 37(2):338-50. PubMed ID: 17274000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 12. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.
    Basset L; Chevalier S; Danger Y; Arshad MI; Piquet-Pellorce C; Gascan H; Samson M
    J Mol Med (Berl); 2015 Dec; 93(12):1355-67. PubMed ID: 26199110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
    Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
    BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
    Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
    Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
    Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
    Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
    Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases-associated interstitial lung disease and interstitial pneumonia with autoimmune features.
    Kameda M; Otsuka M; Chiba H; Kuronuma K; Hasegawa T; Takahashi H; Takahashi H
    PLoS One; 2020; 15(11):e0241719. PubMed ID: 33137121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor.
    Cai W; Wang Z; Cai B; Yuan Y; Kong W; Zhang J; Chen Y; Liu Q; Huang Y; Huang J; Xue W
    Int J Clin Oncol; 2020 Feb; 25(2):338-346. PubMed ID: 31720994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment-related deterioration of renal function is associated with the antitumor efficacy of sunitinib in patients with metastatic renal cell carcinoma.
    Fukuda H; Kondo T; Iida S; Takagi T; Tanabe K
    Urol Oncol; 2016 Aug; 34(8):338.e1-9. PubMed ID: 27085488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.